EQL · EQL Pharma AB · Financials
Market Cap
679.18M SEK
Shares
29.53M
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Browse captured authority reports and their original financial labels
Revenue
432.66M
+15.8%
FY2026
Net Income
12.54M
-70.9%
FY2026
Gross Margin
37.64%
-4.1pp
FY2026
Operating Margin
11.25%
-6.8pp
FY2026
Operating Cash Flow
28.36M
+215%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| SEK | 432.66M | 373.52M | 264.17M |
| SEK | 269.82M | 217.56M | 149.12M |
| SEK | 162.84M | 155.95M | 115.05M |
| SEK | 14.33M | 11.26M | 12.09M |
| SEK | 22.48M | 19.7M | 21.83M |
| SEK | 48.69M | 67.37M | 32.62M |
| SEK | 30.49M | 13.02M | — |
| SEK | 18.21M | 54.35M | 28.6M |
| SEK | 5.67M | 11.23M | 5.9M |
| SEK | 12.54M | 43.12M | 22.71M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current lease liabilities | 2026-03-31 | SEK 2,900,000 | ESEF Annual Report filed 2026-07-24 |
| Noncurrent bonds issued | 2026-03-31 | SEK 342,486,000 | ESEF Annual Report filed 2026-07-24 |
| Noncurrent lease liabilities | 2026-03-31 | SEK 2,687,000 | ESEF Annual Report filed 2026-07-24 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.